Statement By Mike Leavitt Secretary of Health and Human Services
Posted on: Wednesday, 27 September 2006, 12:00 CDT
WASHINGTON, Sept. 27 /PRNewswire/ -- The following is a statement by Mike Leavitt, Secretary of Health and Human Services:
I commend the House of Representatives for passing H.R. 5533, the Biodefense and Pandemic Vaccine and Drug Development Act of 2006. This bipartisan legislation complements important work that we have begun to improve the BioShield program.
Today, HHS is taking important steps forward to improve the way we do business -- to make the biodefense medical countermeasure development and procurement process more streamlined, more transparent and more predictable, in order that medical countermeasures may be developed and acquired more quickly.
H.R. 5533 is an important complement to these efforts, as it supports much needed late-stage research and development funding, and will allow us to make milestone-based advance payments under BioShield.
I commend Representative Mike Rogers, Representative Anna Eshoo and Chairman Joe Barton for their work on this bill, and I look forward to working with Congress to resolve any remaining issues and clear the way for final passage of this bill this year.
Note: All HHS press releases, fact sheets and other press materials are available at http://www.hhs.gov/news.
U.S. Department of Health and Human Services
CONTACT: HHS Press Office, +1-202-690-6343
Web site: http://www.hhs.gov/
Source: PRNewswire
Related Articles
- GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
- Agilent Technologies and BioNanomatrix to Develop Genetic Analysis System Using Nanoscale Whole Genome Imaging Technology
- Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
- Golden Eagle Continues to Develop Important Data From Its C Zone Pilot Gold Operations
- BioCryst and Green Cross Enter Agreement to Develop and Commercialize Peramivir in South Korea
- FermaVir Announces FDA Response to Its Pre-IND Submission for Initial Bioavailability Studies in Human Clinical Trials of FV-100; Response Enables Company to Plan Clinical Development Program for Novel Antiviral Drug Candidate
- FermaVir Announces FDA Response Supports Company's Development Timelines for Key Investigational New Drug Application
- MediVas, LLC Announces Key Appointment for Clinical Development of Biopolymer Vaccine Delivery Program
- California Life Science Leaders Respond to Governor Schwarzenegger's Call to Legalize Importation of Prescription Medicines
- Important Discovery of Gene Involved in Breast and Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds